

# Index

Notes: Drug names appear in **bold** type.

Page numbers in *italics* refer to figures. Page numbers in **bold** refer to tables

- A<sub>1</sub>1 (specific absorbance), 174–175, 195, 197
- absolute configuration, 90
- absolute limit, aspirin, 155
- absolute molarity, 136
- absolute spectrophotometric assays, 175
- absorbance, measurement, 170–171, 193–195, 198
  - infrared spectroscopy, 180–181
  - wavelength *vs.*, 161–163
  - see also* specific absorbance (A<sub>1</sub>1)
- absorption, drugs, 36–39
  - tubocurarine, 55
- acelanilide, aromatic ring oxidation, 109
- acetaminophen *see* paracetamol
- acetic acid (C<sub>2</sub>H<sub>4</sub>O<sub>2</sub>)
  - ammonium salt hydrolysis, 10
  - in buffer solutions, 13
  - pH, 24, 25
  - pK<sub>a</sub>, 8, 61, 61
  - sodium salt, hydrolysis, 25
  - sodium salt hydrolysis, 10
- N-acetylation, 116
- acetyl-β-methylcholine, 238–239
- acetylcholine, 260
- N-acetylcysteine, 118
- acetyl groups, 221
- acid(s), 1–9
  - buffer solutions, 11–14
  - dissociation, 3–9
  - as drugs, 59–63
  - pH, 22
  - pK<sub>a</sub>, 22
  - see also* pH partition hypothesis
- acid-catalysed hydrolysis, 217, 218
- pseudo first-order reactions, 235
- acid diuresis, forced, 49
- acid tartrate, adrenaline, 212
- activation energy (*E*), 236, 239, 268
- active ingredients, concentration, 138
- active mass, 229
- active transport mechanisms, 44–45
- administration, drugs, 36–37, 72
- adrenaline (epinephrine)**, 227
  - enantiomers, 86
  - oxidation, 210–211, 212, 267
  - sulfation, 115
  - synthesis, 86, 87
- adrenaline acid tartrate, 212
- adrenochrome, 212
- ageing, 216–217
- alanine, penicillin, 92
- aldehydes, 209
- aliphatic amines, oxidation, 208
- aliphatic heterocyclic compounds, 73
- aliphatic hydroxylation, 130
- alkaline diuresis, forced, 49
- alkylating agents, 223
- allyl radicals, 208, 225
- aluminium, equivalent weight, 153–154
- amber glass, 213
- amfetamine(s)**
  - deamination, 110
  - metabolism, 120
- amide group(s)
  - hydrolysis, 217, 266
  - as resonance hybrids, 66–67, 67
- amine(s), 209
  - aliphatic, oxidation, 208
  - aromatic, oxidation, 212
  - as basic drugs, 71
  - coupling, 213
  - hydrolysis, 217

- amino acid(s), 16  
 active transport, 44–45  
 as buffers, 16–17  
 chirality, 91, 91–92  
 conjugation, xenobiotics, 115–116  
 amino groups ( $\text{NH}_3^+$ ), 16  
 5-aminosalicylic acid, azoreduction, 111  
 ammonia, as buffer solution, 15  
 ammonium acetate ( $\text{NH}_4\text{C}_2\text{H}_3\text{O}_2$ ),  
 hydrolysis, 10–11  
 ammonium cerium sulfate, REDOX  
 reagents, 150–151  
**ammonium chloride** ( $\text{NH}_4\text{Cl}$ )  
 forced acid diuresis, 49  
 hydrolysis, 9  
 amphiprotic salts, 11  
 amphotericity  
 amino acids, 16–17  
 water, 4  
**ampicillin**, 222, 222  
 analytical spectroscopy, 159–203  
 derivative, 177–179  
 instrumentation, 168–170  
 quantitative aspects, 172–173  
 angiogenesis, thalidomide effects, 98  
 angiotensin II, 227, 268  
 aniline, 165  
 $\lambda_{\text{max}}$ , 164–165  
 anions, 1  
 aniseed oil, 50  
 answers, 253–268  
 anthraquinone, 163  
 anticancer drugs, 37  
 DNA binding, hyperchromic effects,  
 166  
 antioxidants, 213–214, 216  
 aperitifs, 50  
 apoptosis, 216  
 apparent partition coefficient, 31, 56  
 approximate titre calculation, 142  
 argentimetric titrations, 154  
 aromatic compound(s)  
 amines, oxidation, 211  
 heterocyclic, 73  
 light absorption, 163  
 aromatic hydroxylation, 130  
 aromatic ring oxidation, 109  
 Arrhenius plots, 236–237, 239, 268  
**ascorbic acid**  
 antioxidant, 214  
 forced acid diuresis, 49  
 $\text{pK}_a$ , 158, 264  
 titrations, 157, 263–264  
 aspartic acid ( $\text{C}_4\text{H}_7\text{NO}_4$ ), ionisation, 18  
**aspirin**, 62  
 British Pharmacopoeia standards, 138  
 hydrochloric acid, reaction, 238  
 hydrolysis, 220, 227, 238, 267  
 limit tests, 155  
 $\text{pK}_a$ , 62  
 warfarin interactions, 40  
 assay(s)  
 British Pharmacopoeia (BP), 175  
 design, 138–143  
 fats, 215–216  
 monographs, 248–249  
 spectrophotometric methods, 175–177  
 asthma, 23  
 atenolol, 257  
 autoprotolysis constant, water ( $K_w$ ), 2  
 autoxidation, 207  
 fats, 215–216  
 auxochrome(s), 164  
 Avogadro number, 135  
 azoreduction, 111  
 back titration(s), 144–147, 156, 263  
 bacteria, penicillin action, 92  
**barbiturates**, 67–68  
 ionisation, 26–27, 68, 70  
 metabolism, 120  
 tautomerism, 69  
 base(s), 1–9  
 dissociation, 3–9  
 pH, 22  
 $\text{pK}_a$ , 22  
*see also* pH partition hypothesis  
 base-catalysed hydrolysis, 219, 219  
 pseudo first-order reactions, 235  
 baseline technique, infrared spectroscopy,  
 181  
 base peak, mass spectrometry, 192  
 basic drug(s), 71–72  
 basicity constant ( $K_b$ ), 6–8  
 bathochromic shift, 164, 166  
 Beer–Lambert’s equation, 174, 175, 195,  
 265  
 Beer’s Law, 173, 173–174, 193  
 benzaldehyde, 209  
 benzene, 162–163, 163, 265  
 $\lambda_{\text{max}}$ , 164–165  
**benzocaine**, 166

- benzoic acid, amino acid conjugation, 116
- benzyl groups, 266
- benzylisopropylamine, 265–266
- benzyl radicals, 208, 225
- $\beta$  (buffer capacity), 14–15, 28, 254–255
- $\beta$ -lactam antibiotics, 92, 94  
hydrolysis, 267
- bimolecular reaction, 230
- bioactivation, 106
- bioavailability, 36–50, 223
- biotransformation, 105, 106–107  
environmental factors, 107  
genetic factors, 106–107  
pharmacodynamic factors, 107  
physiological factors, 107
- ‘blanking,’ spectrophotometry, 171
- blank titration(s), 144–147
- blood–brain barrier, drug distribution, 37
- blood plasma  
buffer systems, 16–19  
proteins, drug binding, 40
- blue shift(s), 166
- British Anti Lewisite (BAL)**, 260
- British Pharmacopoeia (BP)*, 139, 141, 246–252  
Appendices, 251  
chemical reference substances, 245  
commission, 245  
drug assay methods, 175  
General Notices, 251  
homeopathic medicine, 252  
infrared spectroscopy, 179, 251  
monographs, 85, 139, 246
- British Pharmacopoeia Chemical Reference Substances (BPCRS)*, 245
- bromine, resorcinol assay, 151–152
- Bronsted–Lowry theory, 3, 59
- buffer(s), 11–19, 253–254  
acetate, 14–15  
biological, 16–19  
compleximetric titrations, 152–153  
composition, 11  
partition coefficient measurement, 33
- buffer capacity, 14–15, 28, 254–255
- bupivacaine**, 46, 46
- burettes, 135
- butylated hydroxyanisole (BHA), 214
- butylated hydroxytoluene (BHT), 214
- caffeine**, metabolism, 125
- Cahn–Ingold–Prelog convention, 94, 99, 101, 104  
naloxone hydrochloride, 104  
serine, 96
- calcium  
compleximetric titrations, 153–154  
equivalent weight, 153–154
- calcium carbonate** ( $\text{CaCO}_3$ ), titrations, 145–147
- calibration graph(s), 171–172, 177, 180
- canonical forms, carboxylate anions, 60–61, 61
- capsaicin**, 50–51, 51
- carbohydrate(s), stereoisomers, 90
- carbon–carbon bond(s), 162
- carbonic acid ( $\text{H}_2\text{CO}_3$ ), buffer systems, 16
- carbonyl groups, hydrolysis, 217
- carboxyl groups ( $\text{COO}^-$ ), 17  
ionisation, 60
- carboxylic acids, 59–63  
ionisation, 61
- carvone, chirality, 89, 89
- catechol *O*-methyltransferase (COMT), 119
- cations, 1
- cell membrane(s), 37–39, 38  
pH partition hypothesis, 41
- cells, infrared spectroscopy, 181
- Centralised Procedure, European  
licensing, 242–243
- central nervous system (CNS), drug  
distribution, 37
- cephalosporin**, hydrolysis, 221–222
- cerium, REDOX titrations, 150–151, 157, 263
- chain initiation, oxidation, 206, 206
- chain propagation, oxidation, 206, 206
- chain termination, oxidation, 207, 207
- chalk (calcium carbonate) ( $\text{CaCO}_3$ ),  
titrations, 145–147
- chelating agents, 213
- chemical shift, NMR, 186–187, 188, 265
- chemotherapy, 37
- chirality, 84  
drugs, 84–86
- chloramphenicol**, 225–226
- chloride, reaction with water, 9
- chloroacetic acid,  $\text{pK}_a$ , 8
- chloroamitriptyline**, 100

- chloroform  
 iodine titrations, 152  
 ionisation, 256
- chlorpromazine**, sulfoxidation, 111
- cholesterol, 38, 38–39
- chromatography  
 HPLC *see* high-performance liquid chromatography (HPLC)  
 thin layer, 35
- chromophore(s), 162–163, 200, 265  
 fluorimetry, 182
- cimetidine**  
 CYP450 inhibition, 112  
 metabolism, 125
- ciprofloxacin**, metabolism, 127
- cis-trans* isomerism, 83, 99–100
- citric acid, assay design, 139–141
- clinical data, Marketing Authorisation applications, 244
- cocaine**, 46, 46  
 metabolism, 121  
 specific absorbance, 195
- codeine**, separation from drug mixtures, 75–77
- colorimetry, 159
- coloured compound(s), 163  
*see also* chromophore(s)
- comparative spectrophotometric assay(s), 175–176
- complex cerium salts, REDOX titrations, 150–151, 157, 263
- compleximetric titrations, 152–154
- complexing agents, 152
- concentration (units), 135–137
- conjugate acid, 5
- conjugate base, 8
- conjugated multiple bonds, 162–163
- conjugation reaction(s), 112–119, 131
- Co-Rapporteur, 243
- co-trimoxazole**, 79, 257–258
- counterfeit medicines, 245
- counter ion, drug absorption, 44
- coupling, spin-spin, 187–191, 190
- coupling constant, 190
- curry, 50
- cyanide ions, argentimetric titrations, 154
- cyclophosphamide**, 223
- CYP2D6, 107
- CYP3A4, 107
- cyproheptadine**, metabolism, 123
- cysteamine (mercaptamine)**, 224, 224
- cytochrome P450 monooxygenases (CYP450), 107–111  
 chirality, 119  
 induction, 112  
 inhibitors, 112  
 paracetamol detoxification, 117–118, 118
- D** configuration(s), 90–94
- N*-dealkylation, 109
- O*-dealkylation, 110
- S*-dealkylation, 110
- dealkylation, oxidative, 130
- deamination, 110
- Decentralised Procedure, European licensing, 243–244
- decomposition reactions, 205–227
- delivery pipettes, 134
- deoxyribonucleic acid (DNA) *see* DNA
- depot injections, 215
- derivative spectroscopy, 177–179
- desipramine**, *N*-dealkylation, 109
- detectors, spectrophotometers, 170
- detoxification, 106  
 paracetamol, 117–118
- deuterium, 185  
 exchange, 186  
 lamps, 168
- dextrorotatory compounds, 86
- diamorphine**  
 hydrolysis, 220–221  
 oxidation, 221
- diastereoisomers, 96, 97
- diazepam  
 assays, 201, 265  
 metabolism, 123
- diet, ageing and, 216–217
- diffraction grating(s), 169, 170
- diffusion  
 facilitated, 44  
 passive, 39–40
- digoxin**, 182
- dihydrogenphosphate ( $\text{H}_2\text{PO}_4^-$ ), in buffer solutions, 15
- dilutions, spectrophotometry, 171–172
- dimercaprol**, 103, 260, 260
- dimerisation, 222
- dimethylformamide (DMF), 149
- dipeptides, 92
- diphenoxylate**, metabolism, 123

- discovery chemistry, Marketing  
 Authorisation applications, 244
- disodium edetate**, 152, 213, 214
- disodium hydrogenphosphate  
 ( $\text{Na}_2\text{HPO}_4$ ), in buffer solutions,  
 15
- dissociation, weak acids/bases, 3–9
- dissociation constant  
 acids ( $K_a$ ), 3–9, 59–60  
 base ( $K_b$ ), 6–8
- distomer, 98
- distribution, drugs, 36–39
- diuresis, forced, 49
- DNA  
 drug binding, hyperchromic effects,  
 166  
 oxidative damage, 216
- double bond(s)  
 carbon–carbon, 162  
 infrared spectroscopy, 179
- drug(s)  
 excretion, 48–50  
 ionisation, 19–20  
 licensing, 241–252  
 metabolism *see* metabolism, drugs  
 physicochemical properties, 59–81  
 $\text{p}K_a$ , 20, 21  
 stability *see* stability, drugs
- drug interactions  
 aspirin, 40  
 enzyme induction/inhibition, 111–112  
 warfarin, 40
- drug overdose, 48–49
- paracetamol, 118
- drug resistance, penicillin, 92–94
- drug toxicity, 98
- duplication, assays, 139–140
- dynamic equilibrium, 48
- edetate, disodium**, 152, 213, 214
- EDTA (ethylenediaminetetraacetic acid),  
 213
- E* isomers, 100, 100
- electrochemical detectors, HPLC, 35
- electrolytes, 1
- electromagnetic radiation, 159–164  
 infrared spectroscopy, 179
- electronic transition, 162
- electrons,  $\pi$ , 162
- electron transfer, REDOX titrations,  
 150
- electrophoresis, 17
- electrospray ionisation, 192
- enalaprilate**, 223
- enantiomer(s), 83–84  
 glutamic acid, 17  
 thalidomide, 97–99
- energy, light absorption, spectroscopy,  
 161–163
- environmental chemicals, 105
- enzyme induction, 112
- enzyme(s)  
 chirality, 107, 119  
 DNA repair, 216  
 induction, 111–112  
 inhibition, 112
- ephedrine**, 23, 178, 180  
 chirality, 96  
 metabolism, 122  
 pH, 24  
 solubility, 23, 23, 24  
 structure, 23  
 titration, 28
- epinephrine *see* **adrenaline (epinephrine)**
- $\epsilon$  (molar absorptivity), 174, 175
- equilibria  
 acids/bases, 7  
 dynamic, 48  
 salts, 10–11
- equilibrium constant(s)  
 assay design, 138  
 buffer solutions, 11–12  
 electrolyte dissociation, 1–2, 59  
 weak acids and bases, 4–7  
*see also* dissociation constant
- equivalent relationships, 139
- equivalent weights, 153
- esters, hydrolysis, 217
- ethanol,  $\text{p}K_a$ , 61, 61
- ethanolamine, 28, 253
- ethers, oxidation, 209
- ethoxide anion, 61
- ethylenediaminetetraacetic acid (EDTA),  
 213
- ethyl oleate, 216
- European licensing, 242–244  
 Centralised Procedure, 242–243  
 Decentralised Procedure, 243–244  
 Mutual Recognition Procedure, 243
- European Pharmacopoeia, drug assay  
 methods, 175
- eutomer, 98

- excretion, drugs, 48–50  
 Expert Advisory Groups (EAGs), British Pharmacopoeia, 245  
 external standards, spectrophotometric assays, 176  
 extinction, 175  
 extractions, partition coefficient  
   measurement, 33–34, 51–55, 57, 256–257  
 eye drops, 139, 225–226
- facilitated diffusion, 44  
 factor (f), units of concentration, 135–136  
 fast acetylation, 116  
 fast atom bombardment (FAB), 192  
 fats, autoxidation, 215–216  
**felodipine**, metabolism, 128  
 ferric chloride, salicylic acid limit test, 155  
 Fick's law, 39–40  
 fingerprint region, infrared spectroscopy, 179  
 first-order reactions, 230–233, 238–239, 268  
 Fischer projection(s), 89–94, 101–104  
 fixed oils, autoxidation, 215–216  
 fixed-wavelength spectrophotometer, 168–169  
 fluorimetry, 182–183  
   quenching, 182–183  
 fluorophore, 182  
 food  
   monosodium glutamate, 18, 18  
   partition effects, 50–51  
 forced diuresis, 49  
 formulation, Marketing Authorisation applications, 244, 246  
 free radicals, stability, 207–211  
   substitution, 207–208  
 frequency factor, 236  
 furosemide, 62  
   pK<sub>a</sub>, 62
- gas chromatography–mass spectrometry (GC-MS), 192  
 General Notices, British Pharmacopoeia, 251  
 geometric isomer(s), 83, 99–100  
 glassware  
   colour, 213  
   drying, 149–150  
   glomeruli, 48  
   glucuronides, 113, 113–114  
   glucose, stereoisomers, 86, 88  
   glucuronic acid conjugation, 113–114  
   glutamic acid, 18  
   glutathione, 117  
   glyceraldehyde, stereoisomers, 90, 91  
   glycine  
   conjugation, 115–116  
   ionisation, 17  
 graduated pipettes, 135
- half-life, 233, 235  
 Henderson–Hasselbalch equation  
   buffers, 11–12, 14, 254–255  
   drugs, 19, 21, 26  
**heroin** *see* **diamorphine**  
 hertz (unit), 161  
 heterocyclic compounds, basicity, 73  
 heterocyclic ring oxidation, 109  
 high-performance liquid chromatography (HPLC)  
   chloramphenicol, 225  
   partition coefficients, 35–36  
 hippuric acid, 116  
 homeopathic medicine, British Pharmacopoeia, 252  
**hydralazine**, metabolism, 124  
 hydration, 217, 222  
 hydrochloric acid  
   aspirin, reaction with, 238  
   ephedrine, reaction with, 24  
   stomach, 41–42  
 hydrogen ion(s) (H<sup>+</sup>), concentration, 3  
 hydrogen peroxide, 239  
 hydrolysis, 130, 217–222, 268  
   acid-catalysed, 217, 218  
   amide groups, 266  
   aspirin, 220  
   base-catalysed, 219, 219  
   diamorphine, 220–221  
   functional groups, 218  
   penicillin, 267  
   salts, 9–11  
 hydroperoxide, 206  
 hydroxonium ion, 3, 59  
 hydroxyl ion(s) (OH<sup>-</sup>), in buffer solutions, 13  
 hydroxymethylaminomethane (tris), 13  
 hyperchromicity, 166

- hypochromicity, 166  
 hypsochromic effect, 166
- ibuprofen**  
 glucuronide, 113  
 metabolism, 126  
 side-chain oxidation, 108
- imine–imide tautomerism, 71
- imipramine**  
 metabolism, 124  
 N-dealkylation, 109
- indicator(s)  
 argentimetric titrations, 154  
 assay design, 143, 144, 153, 263  
 compleximetric titrations, 152–154  
 pH, 20–23
- indometacin**, 67, 69  
 metabolism, 122
- infrared light, 160, 160, 162  
 infrared spectroscopy, 179–181, 198  
*British Pharmacopoeia*, 179, 251  
 quantitative analysis, 180–181
- inhibition, enzymes, 112
- initiation, oxidation, 206, 206
- injection vehicles, 215
- insecticides, organophosphorus, 128,  
 128–129
- integration, nuclear magnetic resonance,  
 187
- internal salt(s), active transport, 16, 44
- internal standards, spectrophotometric  
 assays, 176, 185
- intestines, 42, 42–43
- Intraperitoneal Dialysis Solution BPC**,  
 152
- inverted factor, 137
- iodine, REDOX reagents, 150
- iodine flask, 151–152
- ionic product of water, 2
- ionisation  
 ascorbic acid, 264  
 chloroform, 256  
 drugs, 19–20, 30–32, 31, 41  
 mass spectrometry, 191, 192  
 spectroscopic effects, 166
- ion pair, 44
- ions, 1
- iron  
 cytochrome P450 monooxygenase  
 action, 107–108  
 salicylic acid limit test, 155
- isoelectric point (pI), 17
- isomer(s), 83, 83  
 geometric, 83, 99–100  
*see also* enantiomer(s)
- isoniazid**, N-acetylation, 117
- $K_a$  (dissociation constant)  
 acids, 4–5, 7  
 buffer solutions, 12
- $K_b$  (dissociation constant), 6–8
- kidney(s)  
 drug excretion, 48–50  
 drug reabsorption, 48–50
- kinetics  
 drug stability, 229–239  
 electrolyte dissociation, 2
- $K_w$  (autoprotolysis of water), 2
- labetalol**, metabolism, 127
- lactic acid, Fischer projections, 90
- laevorotatory compounds, 86
- $\lambda$  (wavelength of light), 161
- $\lambda_{max}$ , 164, 164, 167
- Lambert's law, 174
- lamp(s)  
 deuterium, 168  
 tungsten, 168  
 xenon arc, fluorimetry, 182
- $L$  configuration(s), 90–94
- levothyroxine (thyroxine)**, 64
- licensing, drugs, 241–252
- lidocaine (lignocaine)**, 46, 46  
 metabolism, 124
- light, 159–164  
 monochromatic, 169  
 sources, 168–169  
*see also* lamp(s)
- lignocaine** *see* lidocaine (lignocaine)
- limit test(s), 154–155, 225
- linoleic acid, 225
- linolenic acid, 225
- lipid bilayers, drug distribution, 39
- liquid chromatography–mass  
 spectrometry (GC-MS), 192
- lithium carbonate (Li<sub>2</sub>CO<sub>3</sub>)**, 155  
 assays, 148–149, 263
- local anaesthetic(s), 45–48  
 pH partition hypothesis, 45–46  
 sink conditions, 47–48
- logarithm(s), 8  
 partition coefficients, 32

- lovastatin**, metabolism, 127
- $\alpha$ -series amino acids, 91, 91–92
- lysine, 28
- ionisation, 28, 255
- magnesium, equivalent weight, 153–154
- malathion, 128, 128–129
- Marketing Authorisation applications, 244–245
- mass action, law of, 2, 43, 231
- mass spectrometry, 191–193
- instrumentation, 191
- mass-to-charge ratio, 191, 265–266
- mathematical derivative, derivative spectroscopy, 177
- mechanism-based inactivation, CYP450, 112
- Medicines and Healthcare products Regulatory Agency (MHRA), 241–242
- divisions, 242
- melphalan**, 45, 45
- membrane(s) *see* cell membrane(s)
- meprobamate**, metabolism, 121
- mepyramine**, 202, 265
- mercaptamine (cysteamine)**, 224, 224
- 6-mercaptopurine**, *S*-dealkylation, 110
- mesomeric effects, aniline, 165
- metabolism, drugs, 105–131, 261
- pathways, 106–107, 120, 120–128
- stereochemistry effects, 119
- metabolite(s), 105
- metabolite intermediate complexation, CYP450, 112
- methadone**, metabolism, 124
- methicillin resistant *Staphylococcus aureus* (MRSA), 93–94
- methotrexate**, 62
- methotrexate,  $pK_a$ , 62
- N*-methylation, 119
- O*-methylation, 119
- methyldopa**, 119, 156
- 6-methylmercaptopurine**, *S*-dealkylation, 110
- methyl orange, 163
- methyl oxidation, 109
- methyl radicals, 208
- mevalonic acid**, 119
- MHRA *see* Medicines and Healthcare products Regulatory Agency (MHRA)
- microvilli, 43, 43
- millimolar equivalent, 153
- mixture(s)
- racemic, 86, 96
- separation, 73–77
- molar absorptivity (*e*), 174, 175
- molarity, 142–143
- mole(s), 135
- molecular ion peak, mass spectrometry, 192
- molecular ion radical, mass spectrometry, 192
- molecularity, 230
- molecular structure, drugs, 183–193
- NMR, 183–191
- monochromator(s), 169–170, 182
- monographs
- assays, 248–249
- British Pharmacopoeia, 85, 139, 246
- purity, 249–251
- triprolidine hydrochloride, 246–251
- monosodium glutamate (MSG), 18, 18
- mordant black, 153
- morphine**, 64, 114, 114, 212
- MRSA (methicillin resistant *Staphylococcus aureus*), 93–94
- multiplicity, 187–191
- mutarotation, 86, 88
- Mutual Recognition Procedure, European licensing, 243
- N*-acetylation, 116
- N*-acetylcysteine, 118, 118
- naloxone hydrochloride**, 104, 261
- N*-dealkylation, 109
- nephron(s), 48, 49
- nephropathic cystinosis, 106, 224
- nicotine, 81, 81
- metabolism, 126
- oxidation, 258, 260
- nitrogen rule, 266
- N*-methylation, 119
- NMR *see* nuclear magnetic resonance (NMR)
- v (hertz), 161
- non-aqueous titrations, 149–150
- non-steroidal anti-inflammatory drug(s)** (NSAIDs)
- amino acid conjugation, 116
- warfarin interactions, 40



- non-synthetic (phase 1) reactions, 106–112, 131, 262–263
- novobiocin**, 226–227, 266–267
- N-oxidation**, 110
- nuclear magnetic resonance (NMR), 183–191, 198–200, 265–266
- instrumentation, 184
  - integration, 187
  - internal standards, 185–186
  - multiplicity, 187–191
  - solvents, 184–185
- nucleophilic attack, ester hydrolysis, 217
- octanol, partition coefficient measurements, 33
- O-dealkylation**, 110
- oils, autoxidation, 215–216
- O-methylation**, 119
- onium ion, 149
- optical density, 175
- optical isomer(s) *see* enantiomer(s)
- order, chemical reactions, 229–230
- organophosphorus insecticide(s), 128
- overdose, drug *see* drug overdose
- oxidation
- ascorbic acid, 263–264
  - cytochrome P450 monooxygenases, 107–108
  - diamorphine, 221
  - drug stability, 205–207, 225
  - nicotine, 258, 260
  - prevention, 211–215
  - REDOX titrations, 150–152
  - see also* autoxidation
- N-oxidation**, 110
- oxidative damage, 216
- DNA, 216
- oxidative **N-dealkylation**, 130
- oxidative **O-dealkylation**, 130
- oxygen, exclusion, 211–213
- paracetamol**, 64, 117–118, 212
- aromatic ring oxidation, 109
  - detoxification, 117–118
  - glucuronide, 113
  - ionization, spectroscopic effects, 166, 166
  - metabolism, 127
  - O-dealkylation**, 110
  - separation from mixtures, 75–77
  - sulfation, 115
- paramagnetic molecules, 205
- partition coefficient(s), 29–57
- experimental measurement, 33–36
- partition law, 30
- Pascal's triangle, 189
- passive diffusion, 39–40
- pastis, 50
- patient information leaflet (PIL), Marketing Authorisation applications, 244
- penicillin(s)**, 92–94, 227
- hydrolysis, 221–222, 267
- pentazocine**, metabolism, 121
- pentobarbital**
- ionisation, 26–27, 27, 68
  - side-chain oxidation, 108
  - structure, 26
- peptidoglycan, bacterial cell walls
- cross-linking, 92
  - penicillin action, 92
- percentage(s)
- of stated amount, 148
  - units of concentration, 138
- percentage transmittance, 174
- perchloric acid, 149–150, 157, 263
- permanganate, potassium salt, standardisation, 150
- peroxide, 206
- pethidine**, metabolism, 121
- pH, 3, 5
- amphiprotic salts, 11
  - buffer solutions, 11
  - effects on spectra, 164–167
  - indicators, 20–23
  - partition coefficients, 30–31
  - $pK_a$  *vs.*, 22
  - salt hydrolysis, 9
  - urine, 49
- pharmacodynamics, 36
- pharmacokinetics, 36
- phase 1 reactions (biotransformation), 106–112, 131, 262–263
- phase 2 reactions (biotransformation), 106, 112–119, 131, 262–263
- phenacetin**, **O-dealkylation**, 110
- phenmetrazine**
- heterocyclic ring oxidation, 109
  - metabolism, 122
- phenol(s), 63–64
- antioxidants, 214
  - oxidation, 210, 210, 266

- phenol(s) (*cont.*)  
 spectral shifts, 162, 166, 167  
 sulfation, 114–115
- phenothiazines**, metabolism, 120
- phenylalanine, 45, 45
- phenylbutazone**, 67
- phenytoin**, 69, 70, 71  
 metabolism, 121
- phocomelia, 97
- phospholipids, 38
- phosphoric acid ( $\text{H}_3\text{PO}_4$ ), in buffer solutions, 15
- photomultiplier tubes,  
 spectrophotometers, 170
- photon(s), 162
- pH partition hypothesis, 40–44  
 limitations, 42–44
- pH titration(s), drug ionisation, 21–22
- physicochemical properties, drugs, 59–81
- pI (isoelectric point), 17
- $\pi$  electrons, 162
- pipettes, 134–135  
 graduated, 135
- piroxicam**, metabolism, 125
- $\text{pK}_a$ , 7–9, 28, 254  
 acids/bases, 22  
 ammonia, 15  
 ascorbic acid, 158, 264  
 buffers, 15, 253  
 drugs, 20, 21  
 pH *vs.*, 22
- plane-polarised light, 84
- plasma *see* blood plasma
- pOH, 15
- poisons, environmental, 105
- polarimetry, 84–88, 85
- polarisation, bonds, hydrolysis, 217
- polymerisation, 222
- potassium cyanide (KCN), argentimetric titrations, 154
- potassium iodide (KI), 151–152
- potassium methoxide ( $\text{CH}_3\text{OK}$ ), 149
- potassium permanganate ( $\text{KMnO}_4$ ), 150
- precipitation, 266–267
- primary standard, 136–137
- prism(s), 169, 169
- procaine**, 72  
 ionisation, 72
- prodrugs, 223–224
- propagation, oxidation, 206, 206
- propranolol**, metabolism, 122
- prostaglandins**, metabolism, 123
- protein(s)  
 as buffers, 16–19  
 drug binding, 43–44  
 sulfation, 114–115
- pseudoephedrine**, chirality, 96
- pseudo first-order reactions, 235
- purity, 196, 263  
 limit tests, 154  
 monographs, 249–251  
 oils, 215–216
- pyridine, 73
- quantitative analysis, infrared spectroscopy, 180–181
- quantitative structure–activity relationships (QSAR), 32
- quaternary ammonium compounds**, 43–44
- quenching, fluorimetry, 182–183
- quinine**, fluorescence, 183, 184
- quinoneimine, 117–118
- racemate(s), 86, 96
- racemic mixture, 86, 96
- radiation, electromagnetic, 159–164
- rancidity, 215
- Rapporteur, 243
- rate constant(s), 229–230  
 first-order reactions, 232, 232  
 second-order reactions, 235  
 temperature effects, 236–238
- rate-determining steps, 229
- rate equations, 230–233
- R configuration(s), 94–96  
 thalidomide, 97
- reabsorption, drugs, 48–50
- recreational drugs, metabolism, 105
- REDOX titrations, 150–152, 263–264
- reduction reaction(s), REDOX titrations, 150–152
- relaxation, 184
- renal tubules, 48
- repair enzymes, DNA, 216
- resonance, 208  
 carboxylate anions, 60–61, 61  
 pentobarbital, 26–27  
 phenoxide anions, 63  
 sulfacetamide, 78  
 tautomerism *vs.*, 66  
 warfarin, 64–66

- resorcinol**, back titrations, 151  
 reversible inhibitors (enzymes), 112  
 rotational transition, 162
- salbutamol**, 212
- salicylic acid**, limit tests, 155
- salt(s)  
   amphiprotic, 11  
   buffer solutions, 11–19  
   hydrolysis, 9–11, 217
- S configuration(s), 94–96  
   thalidomide, 97
- S-dealkylation, 110
- secondary standards, 136–137
- second-order reactions, 230, 234–235
- selective toxicity  
   malathion, 128–129  
   penicillin, 92
- self-quenching, fluorimetry, 183
- separation of mixtures  
   ionisation, use of, 73–77  
   racemic, 96  
   sulfamethoxazole from trimethoprim, 79
- sequestering agents, 152
- serial dilutions, spectrophotometry, 172
- serine, stereoisomerism, 101
- shake flask method, partition coefficients, 33–34
- shelf-life, 233–234
- side-chain oxidation, 108
- silver nitrate ( $\text{AgNO}_3$ ), titrations, 154
- sink conditions, local anaesthetics, 47–48
- slow acetylation, 116
- small intestine, 43  
   pH partition hypothesis, 42–43
- sodium acetate ( $\text{CH}_3\text{CO}_2\text{Na}$ )  
   in buffer solutions, 13  
   hydrolysis, 10  
   pH, 24–25
- sodium bicarbonate** ( $\text{NaHCO}_3$ ), buffer systems, 16
- sodium channels, local anaesthetics on, 47, 47–48
- sodium chloride ( $\text{NaCl}$ )  
   argentimetric titrations, 154  
   hydrolysis, 9
- sodium dihydrogenphosphate ( $\text{NaH}_2\text{PO}_4$ ), in buffer solutions, 15
- sodium hydroxide ( $\text{NaOH}$ ), in buffer solutions, 13
- sodium thiosulfate ( $\text{Na}_2\text{S}_2\text{O}_3$ ), REDOX reagents, 150
- solubility, drugs, 39, 73–74, 266–267  
   *see also* partition coefficient(s)
- solvent(s), 184–185  
   infrared spectroscopy, 181
- specific absorbance ( $A_{11}$ ), 174–175, 195, 197
- spectrofluorimeters, 182
- spectrophotometers, 168–169
- spectroscopy, analytical *see* analytical spectroscopy
- speed of light, 161
- spin–spin coupling, 187–191, 190
- stability, drugs, 205–227  
   free radicals, 207–211  
   kinetics, 229–239  
   Marketing Authorisation applications, 244
- standard additions, spectrophotometric assays, 176, 177
- standardisation, volumetric solutions, 136
- starch, iodine titrations, 151–152
- stereochemistry, 83–104  
   metabolism, effects, 119  
   *see also* enantiomer(s)
- steroids, 38–39
- stoichiometric ratios, assay design, 139
- Stoke's law, 182
- structure–activity relationships, 30  
   quantitative, 32
- substitution, free radical stability, 207–208
- suicide inhibition, CYP450, 112
- sulfacetamide**, 77, 78
- sulfamethoxazole**  
   partition coefficients, 57  
   separation from trimethoprim, 79, 257–258
- sulfanilamide**, 77, 78, 196–197
- sulfapyridine, azoreduction, 111
- sulfasalazine, azoreduction, 111
- sulfate conjugation, 114–115
- sulfathiazole, 196–197
- sulfation, 114–115
- sulfonamides, 69, 70, 71, 71  
   metabolism, 121

- sulfoxidation, 111  
 sulfuric acid ( $\text{H}_2\text{SO}_4$ ), primary standard solutions, 137
- tamoxifen**, 100  
 metabolism, 126
- tandem mass spectrometry (MS-MS), 193
- tautomerism  
   keto–enol, warfarin, 65, 65  
   phenytoin, 71  
   resonance *vs.*, 66
- temperature, effects on reaction rates, 236–238
- terfenadine**, metabolism, 125
- termination, oxidation, 207, 207
- tetrabutylammonium hydroxide ( $\text{N}(\text{Bu}^n)_4\text{OH}$ ), 149
- tetramethylsilane (TMS), 185
- thalidomide**, 97–99
- theophylline**, metabolism, 126
- thin-layer chromatography (TLC),  
   partition coefficients, 35
- thiopental**, 68, 70
- thyroxine (levothyroxine), 64
- titration(s), 141–158  
   approximate titre calculation, 142  
   drug ionisation, 21–22
- tolbutamide**, methyl oxidation, 109
- transfer pipette(s), 134
- trans* isomer(s), 83
- transpeptidase, 92
- transport, active, 44–45
- triglycerides, 215, 215
- trimethoprim**, separation from sulfamethoxazole, 79, 257–258
- trimethylamine**, *N*-oxidation, 110
- tripelennamine**, metabolism, 128
- triple bond(s)  
   carbon–carbon, 162  
   infrared spectroscopy, 179
- Triprolidine hydrochloride**, monograph, 246–251
- tris (hydroxymethylaminomethane), 13
- trituration, 181
- true partition coefficient, 31, 56, 256
- tubocurarine**, drug absorption, 55
- tubules, renal, 48
- tungsten lamps, 168
- ulcers, tubocurarine, 56
- ultraviolet (UV) light, 160, 160, 162  
   deuterium lamps, 168
- ultraviolet (UV) spectroscopy  
   chloramphenicol, 226  
   fluorimetry *vs.*, 182
- unimolecular reactions, 230
- unit-dose medicine, 147–149
- units of concentration, 135–137
- universal gas constant (*R*), 236
- unsaturated fatty acids, 215
- uridine diphosphate glucuronic acid, 113
- urine, pH alterations, 49
- US Pharmacopoeia*, drug assay methods, 175
- valproic acid**, metabolism, 125
- vibrational transitions, 162, 179
- visible spectroscopy, 159–160, 160
- vitamin C *see* ascorbic acid
- volume, units of concentration, 138
- volumetric analysis, 133–158
- volumetric flask, 133, 134
- warfarin**, 64–66  
   aspirin interactions, 40  
   wash bottles, 149
- water  
   amphotericity, 4  
   dissociation, 2  
   as electrolyte, 1  
   salt solution(s), 9–11
- wave frequency, light, 161
- wavelength, light (*l*), 159–162, 160, 161, 161
- wavenumber, 161
- weighing by difference, 141–142
- weight, units of concentration, 138
- xenobiotics  
   enzyme induction, 111–112  
   metabolism, 105
- xenon arc lamps, fluorimetry, 182
- zero-order reactions, 236
- Z* isomers, 99–100, 100
- zwitterion, 16, 17, 255  
   active transport, 44